RENX.L
Strong SellSinkerRenalytix Plc · Healthcare · United Kingdom · $25M · Avg Vol: $172K/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
19
StockRankGet insider-trade alerts
QualityQuality
29
ValueValue
24
MomentumMomentum
48
P/E (TTM)
—
peers 24.9x
ROE
—
peers -4.3%
D/E
—
peers 0.3x
Dividend %
—
trailing yield
ABOUT RENALYTIX PLC
Read
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States.
FINANCIAL SUMMARY (GBP)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 2.2M | 2.5M | 1.7M | 2.2M | 0.3% | 2.5M |
| EPS (GBp) | -9.97 | -8.98 | -8.18 | -5.23 | — | -3.00 |
| Shares | 437.0M | 437.0M | 437.0M | 331.2M | -24.2% | — |
| Debt | 9.2M | 9.1M | 6.4M | 6.2M | -12.4% | 4.3M |
| Equity | 22.9M | 5.2M | -6.7M | -5.2M | -77.2% | — |
| Op CF | -34.3M | -25.5M | -22.3M | -13.4M | — | -9.7M |
| Inv CF | -0.5M | 0 | 74.7K | 0 | — | — |
| Fin CF | 19.2M | 12.2M | 7.5M | 12.0M | — | — |
Loading 1Y...
PRICE (1Y)+95.2%
SMA 50SMA 200
Close
$0.0823
RSI (14)
82.3
52W High
$0.1572
From 52W High
0.5%
SCORE BREAKDOWN
Quality
29
ROIC
-1638.5%0.2
ROE
—N/A
GP/Assets
24.6%53.4
Op. Margin
-437.5%10.5
FCF/Assets
—N/A
Piotroski
668.6
Int. Cover
-42.6x12.5
D/E Ratio
—N/A
Current Ratio
1.57x28.3
Value
24
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
-37.6x25.0
P/S
15.3x18.7
Div Yield
—N/A
Momentum
48
52W High %
52%26.4
RS 6M
132%97.8
SMA 50/200
1.06x69.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-200%2.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$25M
P/E (Forward)
-0.7x
Gross Margin
45.5%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RENX.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RENX.L | Renalytix Plc(you) | $25M | 19 | Strong Sell |
| MPAL.L | MedPal AI PLC | $46M | 15 | Strong Sell |
| DXRX.L | Diaceutics PLC | $164M | 62 | Hold |
| OPT.L | Optima Health plc | $359M | 63 | Hold |
| KOO.L | Kooth plc | $96M | 94 | Strong Buy |
| GDR.L | genedrive plc | $30M | 20 | Sell |
| CRW.L | Craneware plc | $646M | 64 | Hold |
| IXI.L | IXICO plc | $25M | 29 | Sell |
| CLBX.L | CelLBxHealth plc | $39M | 16 | Strong Sell |
| SBTX.L | SkinBioTherapeutics plc | $33M | 11 | Strong Sell |
Peer medians: ROE -4.3% · P/E 24.9x · Gross margin 56.8%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.